相关实验视频

Updated: May 5, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

从结构生物学中吸取的教训,以了解胃肠道瘤 (GIST) 中的耐药性

Giorgia Mancino^1,2, Tom Schulz^1,2, Andrea Scrima^1,2

¹Department of Chemistry and Chemical Biology, TU Dortmund University, Dortmund, Otto-Hahn-Strasse 4a, 44227 Dortmund, Germany.

Journal of medicinal chemistry

|March 2, 2026

概括

胃肠道 stromal 瘤 (GIST) 的药物耐药性源于 KIT 或 PDGFRA 激酶的二次突变. 了解这些结构变化是开发克服耐药性的新疗法的关键.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

胃肠道 stromal 瘤 (GIST) 是由KIT或PDGFRA受体氨酸激酶的突变驱动的.
针对性疗法,如氨酸激酶抑制剂 (TKIs),改善了GIST患者的治疗结果.
获得的耐药性仍然是一个重大挑战,限制了这些治疗的长期有效性.

研究的目的:

审查对GISTs获得药物耐药性的分子机制的结构性见解.
阐明KIT和PDGFRA激酶中的二级和三级突变如何导致TKI耐药性.
要突出激酶激活,TKI结合和抗性突变之间的相互作用.

主要方法:

这项研究是一个视角的作品,综合了现有的研究和结构数据.
对已发表的关于GIST突变,激酶结构和耐药性机制的文献进行分析.
专注于结构生物学对酶域改变的洞察力.

主要成果:

在不同的激酶域区域中发生的二次和三次突变会改变激酶构造和TKI结合.
特定突变破坏了参与药物相互作用或激酶活性调节的关键残留物.
这些变化导致TKI疗效降低和治疗失败.

结论:

深入了解GIST耐药性的结构基础是必不可少的.
识别抗性突变模式可以指导下一代技术知识的发展.
未来的治疗策略必须解决潜在的获得性耐药性的分子机制,以改善长期GIST管理.

更多相关视频

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

相关概念视频

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...